Abstract

Could or Should We Use Cost-Effectiveness Thresholds in the French Value-Based Pricing Process for New Drugs?

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call